Compare Adaptive Biotechnologies Corp (ADPT) vs Banco Santander SA (SAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Banco Santander SA — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Banco Santander SA trades at $13.57 (market cap $203.67B). The key difference: Banco Santander SA is far larger — about 61.2× Adaptive Biotechnologies Corp's market cap, and Banco Santander SA pays a 1.96% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SAN | |
|---|---|---|
Market Cap | $3.33B | $203.67B |
Sector | Health | Financials |
52-Week High | $22.37 | $14.37 |
52-Week Low | $10.24 | $8.31 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Banco Santander (SAN) trades at $14.19, up 1.72% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 26.72% net income margin and 16.18% ROE, though recent quarters saw EPS misses. Recent developments include the completion of the TSB acquisition and AI-driven efficiency initiatives, positioning the company for growth amid positive analyst sentiment.
The outlook for SAN is cautiously optimistic, with upside driven by cost-saving measures and strategic acquisitions. Risks include regulatory scrutiny in Spain and volatile cash flows. Analysts maintain a 64% buy rating, highlighting value potential, but investors should monitor execution on profitability targets and macroeconomic impacts on banking sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
